Holen Sie sich die Stockscreener-App
16.30
2.28%
-0.38
Handel nachbörslich:
16.30
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
(JANX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Janux Therapeutics: It's Too Early To Tell If Prostate Cancer Program Can Succeed (JANX) - Seeking Alpha
Here's Why You Should Add JANX Stock to Your Portfolio Now - Eastern Progress
Wall Street Analysts Predict a 155.82% Upside in Janux Therapeutics (JANX): Here's What You Should Know - Eastern Progress
Janux Therapeutics, Inc. (JANX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare ConferenceSlideshow (NASDAQ:JANX) 2026-09-17 - Seeking Alpha
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux - Yahoo Finance
4 Prostate Cancer Drug Stocks to Watch During Awareness Month - finance.yahoo.com
Janux doses first patient in JANX013 prostate cancer trial By Investing.com - Investing.com India
Janux Therapeutics Doses First Participant in Phase 1 Study of Prostate Cancer Candidate - marketscreener.com
Janux Therapeutics doses first patient in Phase 1 study: Will JANX hold $17.07 support? - Traders Union
Janux doses first patient in JANX013 prostate cancer trial - Investing.com
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013 - Yahoo Finance Australia
Price-Driven Insight from (JANX) for Rule-Based Strategy - Stock Traders Daily
Janux’s New Prostate Cancer Combo Trial: What Early Signals Could Mean for JANX - TipRanks
Janux’s JANX014 Prostate Cancer Trial Advances, Keeping Early-Stage Upside in Play - TipRanks
Understanding the Setup: (JANX) and Scalable Risk - Stock Traders Daily
How Much Upside is Left in Janux Therapeutics (JANX)? Wall Street Analysts Think 180.44% - qz.com
Wolfe Research Initiates Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $23 - Moomoo
Wolfe Research upgrades Janux stock rating on autoimmune data By Investing.com - Investing.com Canada
Wolfe Research upgrades Janux stock rating on autoimmune data - Investing.com
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
JANX Q2 2026 Earnings: Narrower-Than-Expected Loss Supports Clinical-Stage ProgressPost-Earnings Drift - dars.gov.et
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - Stock Titan
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - Stock Titan
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
JANX: Clinical pipeline advanced and net loss narrowed, supported by nearly $1B in liquidity - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M - marketscreener.com
JANX: Revenue from BMS collaboration boosted H1 2026 results; net loss narrowed, cash remains strong - TradingView
Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue - Stock Titan
Janux Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Janux Therapeutics posts $970.9M cash; Q2 net loss $22.0M and revenue $10.3M - TradingView
3.06%
2.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):